Some readers of The “New” Prostate Cancer InfoLink will be interested in a new article with the above title by Prof. Emil Freireich, MD, that appears in the most recent issue of The ASCO Post. Professor Freireich’s opinion is certainly stimulating, although the problem as described and the solution as proposed may not be quite as straightforward as suggested.
Filed under: Drugs in development | Tagged: drug development, FDA | Leave a comment »
We have commented before on the potential of epigenetics in the development of innovative therapies for the management of prostate cancer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: drug development, epigenetics, epigenome, review, vorinostat | Leave a comment »
If you’ve been hoping that research in the field of epigenetics is going to bring us a cure for prostate cancer in the next few years, dream on! … READ MORE …
Filed under: Drugs in development | Tagged: drug development, epigenetics | 3 Comments »
Topics in the news today address: prostate cancer grade migration over time; yet another new radiotherapy option for early stage disease (but the data are very early); and a new model for assessing efficacy of development-stage drugs. … READ MORE …
Filed under: Diagnosis, Drugs in development, Treatment | Tagged: drug development, grade migration, pHART3, radiotherapy | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 